Temozolomide is a novel cytotoxic agent for malignant gliomas. However, treatment failure occurs approximately in half of patients, and the optimal regimen in this setting has yet to be defined. In the present study, we assessed retrospectively the efficacy and toxicity of the combination of carboplatin and oral cyclophosphamide in temozolomide-resistant patients.
Methods
We evaluated the medical records of 30 patients with malignant gliomas. After failure of temozolomide therapy, patients were treated with a combination of carboplatin and oral cyclophosphamide. Treatment consisted of intravenous carboplatin AUC 6 (based on the Calvert Formula) on day 1 and oral cyclophosphamide 75 mg/m2 daily on days 1 to 14, followed by 14 days of rest, with the treatment repeated every 4 weeks.
Results
All patients were evaluated for response and toxicity. The objective response rate was 30%, including 9 partial responses. Median time to disease progression and median overall survival was 7 months and 8 months, respectively. Clinically responsive patients had statistically significant longer progression-free survival and overall survival than unresponsive patients. Hematological side effects were commonly observed toxicities, with neutropenia the most frequent.
Conclusions
Our data suggest that carboplatin and oral cyclophosphamide therapy is a convenient regimen after failure of temozolomide therapy in patients with malignant gliomas because of its activity, feasibility and tolerability. Further prospective studies are needed in this setting.
SoffiettiR., RudàR., TrevisanE.: New chemotherapy options for the treatment of malignant gliomas. Anti-cancer Drugs, 18: 621–631, 2007.
2.
BucknerJ.C.: Factors influencing survival in high grade gliomas: Semin Oncol, 30 (Suppl 19): 10–14, 2003.
3.
YungW.K., AlbrightR.E., OlsonJ., FredericksR., FinkK., PradosM.D., BradaM., SpenceA., HohlR.J., ShapiroW., GlantzM., GreenbergH., SelkerR.G., VickN.A., RamplingR., FriedmanH., PhillipsP., BrunerJ., YueN., OsobaD., ZaknoenS., LevinV.A.: A phase II study of temozolomide vs procarbazine in patients with glioblastoma at first relapse. Br J Cancer, 83: 588–593, 2000.
4.
BradaM., Hoang-XuanK., RamplingR., DietrichP.Y., DirixL.Y., MacdonaldD., HeimansJ.J., ZonnenbergB.A., Bravo-MarquesJ.M., HenrikssonR., StuppR., YueN., BrunerJ., DuganM., RaoS., ZaknoenS.: Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol, 12: 259–266, 2001.
5.
YungW.K., PradosM.D., Yaya-TurR., RosenfeldS.S., BradaM., FriedmanH.S., AlbrightR., OlsonJ., ChangS.M., O'NeillA.M., FriedmanA.H., BrunerJ., YueN., DuganM., ZaknoenS., LevinV.A.: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group. J Clin Oncol, 17: 2762–2771, 1999.
6.
StuppR., GanderM., LeyvrazS., NewlandsE.: Current and future developments in the use of temozolomide for the treatment of brain tumors. Lancet Oncol, 2: 552–560, 2001.
7.
BrandesA.A., TosoniA., BassoU., ReniM., ValdugaF., MonfardiniS., AmistàP., NicolardiL., SottiG., ErmaniM.: Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first line temozolomide chemotherapy: A phase II study of the Gruppo Italiona Cooperativo di Neuro-Oncologia (GIC-NO). J Clin Oncol, 22: 4779–4786, 2004.
8.
KappelleA.C., PostmaT.J., TaphoornM.J., GroeneveldG.J., van den BentM.J., van GroeningenC.J., ZonnenbergB.A., SneeuwK.C., HeimansJ.J.: PVC chemotherapy for recurrent glioblastoma multiforme. Neurology, 56: 118–120, 2001.
9.
ReardonD.A., EgorinM.J., QuinnJ.A., RichJ.N., GururanganS., VredenburghJ.J., DesjardinsA., SathornsumeteeS., ProvenzaleJ.M., HerndonJ.E.2nd, DowellJ.M., BadruddojaM.A., McLendonR.E., LagattutaT.F., KicielinskiK.P., DresemannG., SampsonJ.H., FriedmanA.H., SalvadoA.J., FriedmanH.S.: Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma. J Clin Oncol23: 9359–9369, 2005.
10.
DresemannG.: Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol, 16: 1702–1706, 2005.
11.
DesjardinsA., QuinnJ.A., VredenburghJ.J., SathornsumeteeS., FriedmanA.H., HerndonJ.E., McLendonR.E., ProvenzaleJ.M., RichJ.N., SampsonJ.H., GururanganS., DowellJ.M., SalvadoA., FriedmanH.S., ReardonD.A.: Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol, 83: 53–60, 2007.
12.
RaizerJ.J.: HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neuro-Oncol, 74: 77–86, 2005.
13.
RichJ.N., ReardonD.A., PeeryT, RichJ.N., ReardonD.A., PeeryT., DowellJ.M., QuinnJ.A., PenneK.L., WikstrandC.J., Van DuynL.B., DanceyJ.E., McLendonR.E., KaoJ.C., StenzelT.T., Ahmed RasheedB.K., Tourt-UhligS.E., HerndonJ.E.2nd, VredenburghJ.J., SampsonJ.H., FriedmanA.H., BignerD.D., FriedmanH.S.: Phase II study of gefitinib in recurrent glioblastoma. J Clin Oncol, 22: 133–142, 2004.
14.
VredenburghJ.J., DesjardinsA., HerndonJ.E.2nd, DowellJ.M., ReardonD.A., QuinnJ.A., RichJ.N., SathornsumeteeS., GururanganS., WagnerM., BignerD.D., FriedmanA.H., FriedmanH.S.: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res, 15: 1253–1259, 2007.
PoissonM., PereonY., ChirasJ., DelattreJ.Y.: Treatment of recurrent malignant supratentorial gliomas with carboplatin. J Neurooncol, 10: 139–144, 1991.
17.
JeremicB., GrujicicD., JevremovicS., StanisavljevicB., MilojevicL., DjuricL., MijatovicL.: Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J Clin Oncol, 10: 1074–1077, 1992.
18.
YungW.K., MechtlerL., GleasonM.J.: Intravenous carboplatin for recurrent glioma: a phase II study. J Clin Oncol, 9: 860–864, 1991.
19.
SteinM.E., KutenA., DrumeaK., GoldsherD., Tzuk-ShinaZ.: Carboplatin and etoposide for recurrent malignant glioma following surgical and radiotherapy failure. A clinical study conducted at the Northern Israel Oncology Center. J Surg Oncol, 71: 167–170, 1999.
20.
WatanebeK., KanayaH., FujiyamaY., KimP.: Combination chemotherapy using carboplatin (JM-8) and etoposide (JET) chemotherapy for recurrent malignant gliomas: A Phase II study. Acta Neurochir, 144: 1265–1270, 2002.
21.
ViñolasN., GilM., VergerE., VilláS., PujolT., CeralL., GarcíaM., GrausF.: Pre-irradiation semi-intensive chemotherapy with carboplatin and cyclophosphamide in malignant glioma: a phase II study. Anticancer Drugs, 13: 163–167, 2002.
22.
ChamberlainM., Tsao-WeiD.D.: Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. Cancer, 100: 1213–1220, 2004.
23.
KleihuesP., CaveneeWK (Eds): Pathology and genetics of tumors of the nervous system: In: World Health Organization Classification of the Tumors of the Nervous system, Editorial and Consensus Conference Working Group.IARC Press, Lyon, 2000.
24.
MillerA.B., HoogstratenB., StaquetM.: Reporting results of cancer treatment. Cancer, 47: 207–214, 1981.
25.
National Cancer Institute Toxicity Criteria Version 3.0 ctep.cancer.gov/forms/CTCAEv3.pdf.Nervous System Consortium.
26.
FetellM.R., GrossmanS.A., FisherJ.D., ErlangerB., RowinskyE., StockelJ., PiantadosiS.: Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol, 15: 3121–3128, 1997.
27.
KuhnJ.G.: Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. Oncology (Huntingt), 16: 33–40, 2002.
StuppR., MasonW.P., van den BentM.J., WellerM., FisherB., TaphoornM.J., BelangerK., BrandesA.A., MarosiC., BogdahnU., CurschmannJ., JanzerR.C., LudwinS.K., GorliaT., AllgeierA., LacombeD., CairncrossJ.G., EisenhauerE., MirimanoffR.O.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastomas. N Engl J Med, 352: 987–997, 2005.
30.
AmmiratiM., GalicichJ.H., ArbitE., LiaoY.: Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery, 21: 607–614, 1987.
31.
HarshGR4th, LevinV.A., GutinP.H., SeagerM., SilverP., WilsonC.B.: Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery, 21: 615–621, 1987.
32.
DirksP., BernsteinM., MullerP.J., TuckerW.S.: The value of reoperation for recurrent glioblastoma. Can J Surg, 36: 271–275, 1993.
TsaoM.N., MehtaM.P., WhelanT.J., MorrisD.E., HaymanJ.A., FlickingerJ.C., MillsM., RogersC.L., SouhamiL.: The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys, 2005, 63: 47–55, 2005.
35.
ZhouQ., GuoP., WangX., NuthalapatiS., GalloJ.M.: Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. J Pharmacol Exp Ther, 321: 265–275, 2007.
36.
CaroliM., LocatelliM., CampanellaR., MottaF., MoraA., PradaF., BorsaS., Martinelli-BoneschiF., SaladinoA., GainiS.M.: Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol? J Neurooncol, 84: 71–77, 2007.
37.
BrandesA.A., PasettoL.M., VastolaF., MonfardiniS.: Temozolomide in patients with high-grade glioma. Oncology, 59: 181–186, 2000.
38.
BrandesA.A., BassoU., ReniM., VastolaF., TosoniA., CavalloG., ScopeceL., FerreriA.J., PanucciM.G., MonfardiniS., ErmaniM.: Gruppo Italiano Cooperativo di Neuro-Oncologia. Firstline chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a pahse ii study of the Gruppo Italiano Cooperativo di Neuro-Oncologica. J Clin Oncol, 22: 1598–1604, 2004.
39.
SilvaniA., EoliM., SalmaggiA., LampertiE., MaccagnanoE., BroggiG., BoiardiA.: Phase II trial of cisplatin plus temozolomide in recurrent and progressive malignant glioma patients. J Neuroncol, 66: 203–208, 2004.
